bioAffinity Technologies, Inc. Cash Flow Statement
BIAF|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
bioAffinity Technologies, Inc. used $7M in operating cash flow and negative free cash flow of $7M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| Depreciation & Amortization | $605.6K | $249.6K | $10.2K | $4.8K |
| Operating Cash Flow | -$7.3M | -$6.0M | -$4.1M | -$2.0M |
| Capital Expenditures | $79.1K | $22.9K | $220.0K | $220.0K |
| Free Cash Flow | -$7.3M | -$6.1M | -$4.3M | -$2.3M |
| FCF Margin | -78.4% | -239.3% | -62.2% | -47240.6% |